Radiation-induced modifications of the tumor microenvironment promote metastasis

Bulletin du Cancer

Volumn 98, Issue 6, 2011, Pages

  Rüegg, Curzio ^a,b,c   Monnier, Yan ^a,c   Kuonen, François ^a,c   Imaizumi, Natsuko ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF FRIBOURG   (Switzerland)

^c EPFL   (Switzerland)

Author keywords

Angiogenesis; CYR61; Integrins; Invasion; Metastasis; Radiotherapy; TGF ; Tumor bed effect; V 5

Indexed keywords

ALPHAVBETA5 INTEGRIN; ANGIOGENESIS INHIBITOR; CILENGITIDE; CYSTEINE RICH PROTEIN 61; FIBROBLAST GROWTH FACTOR 2; PROTEIN P16; PROTEIN P21; PROTEIN P53; SPHINGOSINE 1 PHOSPHATE; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; APOPTOSIS; ARTERY OCCLUSION; B LYMPHOCYTE; BACTERIAL INFECTION; CANCER INVASION; CELL CYCLE ARREST; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CELL SELECTION; CELL SURVIVAL; DEHYDRATION; DIARRHEA; DISTANT METASTASIS; ENDOTHELIUM CELL; GENE EXPRESSION; GLIOBLASTOMA; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; HYPOXIA; IONIZING RADIATION; LUNG METASTASIS; METASTASIS; NONHUMAN; RADIATION DOSE; RADIATION INDUCED NEOPLASM; RADIATION INJURY; RADIATION PROTECTION; REVIEW; SEPTIC SHOCK; STROKE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR NECROSIS; TUMOR VASCULARIZATION; WESTERN BLOTTING;

EID: 79959328317     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2011.1372     Document Type: Review

References (86)

1. Bernier J, Hall EJ, Giaccia A. Radiation oncology: a century of achievements. Nat Rev Cancer 2004 ; 4 : 737-47.
2. Gudkov AV, Komarova EA. The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer 2003 ; 3 : 117-29. (Pubitemid 37328879)
3. Barcellos-Hoff MH, Park C, Wright EG. Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer 2005 ; 5 : 867-75. (Pubitemid 41746031)
4. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003 ; 300 : 1155-9. (Pubitemid 36583102)
5. Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001 ; 345 : 1378-87.
6. Vicini FA, Kestin L, Huang R, Martinez A. Does local recurrence affect the rate of distant metastases and survival in patients with early-stage breast carcinoma treated with breast-conserving therapy? Cancer 2003 ; 97 : 910-9.
7. Vikram B, Strong EW, Shah JP, Spiro R. Failure at distant sites following multimodality treatment for advanced head and neck cancer. Head Neck Surg 1984 ; 6 : 730-3. (Pubitemid 14185490)
8. Suit HD. Local control patient survival. Int J Radiat Oncol Biol Phys 1992 ; 23 : 653-60.
9. O'Brien CJ, Smith JW, Soong SJ, Urist MM, Maddox WA. Neck dissection with and without radiotherapy: prognostic factors, patterns of recurrence and survival. Am J Surg 1986 ; 152 : 456-63. (Pubitemid 16001482)
10. Milas L, Hirata H, Hunter N, Peters LJ. Effect of radiation-induced injury of tumor bed stroma on metastatic spread of murine sarcomas and carcinomas. Cancer Res 1988 ; 48 : 2116-20.
11. Milas L, Hunter N, Peters LJ. The tumor bed effect: dependence of tumor take, growth rate, and metastasis on the time interval between irradiation and tumor cell transplantation. Int J Radiat Oncol Biol Phys 1987 ; 13 : 379-83. (Pubitemid 17053951)
12. Woodward WA, Truong PT, Yu TK, et al. Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival. Breast Cancer Res Treat 2010 ; 123 : 597-605.
13. Rofstad EK. Microenvironment-induced cancer metastasis. Int J Radiat Biol 2000 ; 76 : 589-605. (Pubitemid 30345160)
14. Rofstad EK, Mathiesen B, Henriksen K, Kindem K, Galappathi K. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res 2005 ; 65 : 2387-96. (Pubitemid 40490150)
15. Kozin SV, Winkler F, Garkavtsev I, Hicklin DJ, Jain RK, Boucher Y. Human tumor xenografts recurring after radiotherapy are more sensitive to anti-vascular endothelial growth factor receptor-2 treatment than treatment-naive tumors. Cancer Res 2007 ; 67 : 5076-82. (Pubitemid 46997241)
16. Bonnaud S, Niaudet C, Pottier G, et al. Sphingosine-1-phosphate protects proliferating endothelial cells from ceramide-induced apoptosis but not from DNA damage-induced mitotic death. Cancer Res 2007 ; 67 : 1803-11. (Pubitemid 46389242)
17. Nieder C, Wiedenmann N, Andratschke NH, Astner ST, Molls M. Radiation therapy plus angiogenesis inhibition with bevacizumab: rationale and initial experience. Rev Recent Clin Trials 2007 ; 2 : 163-8. (Pubitemid 47554836)
18. Fenton BM, Paoni SF. The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res 2007 ; 67 : 9921-8. (Pubitemid 47621241)
19. Shinohara ET, Cao C, Niermann K, et al. Enhanced radiation damage of tumor vasculature by mTOR inhibitors. Oncogene 2005 ; 24 : 5414-22. (Pubitemid 43080085)
20. Wachsberger P, Burd R, Dicker AP. Improving tumor response to radiotherapy by targeting angiogenesis signaling pathways. Hematol Oncol Clin North Am 2004 ; 18 : 1039-57. (Pubitemid 39335758)
21. Fajardo LF. The pathology of ionizing radiation as defined by morphologic patterns. Acta Oncol 2005 ; 44 : 13-22. (Pubitemid 40249124)
22. Tetik O, Yetkin U, Calli AO, Ilhan G, Gurbuz A. Occlusive arterial disease after radiotherapy for testicular cancer: case report and review of the literature. Vascular 2008 ; 16 : 239-41.
23. Group EBCTC. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Lancet 2000 ; 355 : 1757-70.
24. Dorresteijn LD, Kappelle AC, Scholz NM, et al. Increased carotid wall thickening after radiotherapy on the neck. Eur J Cancer 2005 ; 41 : 1026-30. (Pubitemid 40602854)
25. Little MP, Tawn EJ, Tzoulaki I, et al. A systematic review of epidemiological associations between low and moderate doses of ionizing radiation and late cardiovascular effects, and their possible mechanisms. Radiat Res 2008 ; 169 : 99-109. (Pubitemid 351295097)
26. Potten CS. A comprehensive study of the radiobiological response of the murine (BDF1) small intestine. Int J Radiat Biol 1990 ; 58 : 925-73.
27. Paris F, Fuks Z, Kang A, et al. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 2001 ; 293 : 293-7. (Pubitemid 32694744)
28. Maj JG, Paris F, Haimovitz-Friedman A, Venkatraman E, Kolesnick R, Fuks Z. Microvascular function regulates intestinal crypt response to radiation. Cancer Res 2003 ; 63 : 4338-41. (Pubitemid 36951000)
29. Kirsch DG, Santiago PM, di Tomaso E, et al. p53 controls radiation-induced gastrointestinal syndrome in mice independent of apoptosis. Science 2010 ; 327 : 593-6.
30. Dormand EL, Banwell PE, Goodacre TE. Radiotherapy wound healing. Int Wound J 2005 ; 2 : 112-27.
31. Imaizumi I, Monnier Y, Hegi M, Mirimanoff RO, Rüegg C. Radiotherapy suppresses angiogenesis in mice through TGF-βRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoSONE 2010 [in press].
32. Fei P, El-Deiry WS. P53 and radiation responses. Oncogene 2003 ; 22 : 5774-83. (Pubitemid 37176699)
33. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest 1994 ; 93 : 892-9.
34. Randall K, Coggle JE. Expression of transforming growth factor-beta 1 in mouse skin during the acute phase of radiation damage. Int J Radiat Biol 1995 ; 68 : 301-9.
35. Barcellos-Hoff MH, Costes SV. A systems biology approach to multicellular and multi-generational radiation responses. Mutat Res 2006 ; 597 : 32-8.
36. Monnier Y, Farmer P, Bieler G, et al. CYR61 and alphaV-beta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res 2008 ; 68 : 7323-31.
37. Leith JT, Padfield G, Quaranto L, Michelson S. Effect of preirradiation of transplantation site on growth characteristics and hypoxic fractions in human colon tumor xenografts. Cancer Res 1992 ; 52 : 2162-6.
38. Penhaligon M, Courtenay VD, Camplejohn RS. Tumour bed effect: hypoxic fraction of tumours growing in preirradiated beds. Int J Radiat Biol Relat Stud Phys Chem Med 1987 ; 52 : 635-41. (Pubitemid 17153774)
39. Hockel M, Schlenger K, Hockel S, Aral B, Schaffer U, Vaupel P. Tumor hypoxia in pelvic recurrences of cervical cancer. Int J Cancer 1998 ; 79 : 365-9. (Pubitemid 28359734)
40. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res 2001 ; 61 : 8903-8. (Pubitemid 34013907)
41. Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002 ; 86 : 301-8. (Pubitemid 34185162)
42. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999 ; 53 : 113-7.
43. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996 ; 56 : 4509-15. (Pubitemid 26330463)
44. Brizel DM, Scully SP, Harrelson JM, et al. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996 ; 56 : 941-3. (Pubitemid 26065381)
45. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002 ; 2 : 38-47. (Pubitemid 37328806)
46. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006 ; 441 : 437-43. (Pubitemid 44050138)
47. Gassmann M, Kvietikova I, Rolfs A, Wenger RH. Oxygen- and dioxin-regulated gene expression in mouse hepatoma cells. Kidney Int 1997 ; 51 : 567-74. (Pubitemid 27088178)
48. Paez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009 ; 15 : 220-31.
49. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006 ; 119 : 4803-10. (Pubitemid 46017793)
50. Lau LF, Lam SC. The CCN family of angiogenic regulators: the integrin connection. Exp Cell Res 1999 ; 248 : 44-57. (Pubitemid 29393928)
51. Menendez JA, Mehmi I, Griggs DW, Lupu R. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocr Relat Cancer 2003 ; 10 : 141-52. (Pubitemid 36758643)
52. Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest 1997 ; 99 : 1390-8. (Pubitemid 27142777)
53. Enns A, Korb T, Schluter K, et al. Alphavbeta5-integrins mediate early steps of metastasis formation. Eur J Cancer 2005 ; 41 : 1065-72. (Pubitemid 40602860)
54. Felding-Habermann B. Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis 2003 ; 20 : 203-13. (Pubitemid 36513225)
55. Mitjans F, Sander D, Adan J, et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995 ; 108 : 2825-38.
56. Dechantsreiter MA, Planker E, Matha B, et al. N-Methylated cyclic RGD peptides as highly active and selective alpha(V) beta(3) integrin antagonists. J Med Chem 1999 ; 42 : 3033-40.
57. Barton M. Tables of equivalent dose in 2 Gy fractions: a simple application of the linear quadratic formula. Int J Radiat Oncol Biol Phys 1995 ; 31 : 371-8.
58. Brown JM, Koong AC. High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys 2008 ; 71 : 324-5.
59. Tan J, Geng L, Yazlovitskaya EM, Hallahan DE. Protein kinase B/Akt-dependent phosphorylation of glycogen synthase kinase-3beta in irradiated vascular endothelium. Cancer Res 2006 ; 66 : 2320-7.
60. Sofia Vala I, Martins LR, Imaizumi N, et al. Low doses of ionizing radiation promote tumor growth and metastasis by enhancing angiogenesis. PLoSONE 2010 ; 5 : e11222.
61. Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 2008 ; 173 : 1173-85.
62. Ahn GO, Brown JM. Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell 2008 ; 13 : 193-205.
63. Allan DS, Morgan SC, Birch PE, et al. Mobilization of circulating vascular progenitors in cancer patients receiving external beam radiation in response to tissue injury. Int J Radiat Oncol Biol Phys 2009 ; 75 : 220-4.
64. Kioi M, Vogel H, Schultz G, Hoffman RM, Harsh GR, Brown JM. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J Clin Invest 2010 ; 120 : 694-705.
65. Klopp AH, Spaeth EL, Dembinski JL, et al. Tumor irradiation increases the recruitment of circulating mesenchymal stem cells into the tumor microenvironment. Cancer Res 2007 ; 67 : 11687-95.
66. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006 ; 25 : 435-57.
67. Park CC, Bissell MJ, Barcellos-Hoff MH. The influence of the microenvironment on the malignant phenotype. Mol Med Today 2000 ; 6 : 324-9.
68. Kim IY, Kim MM, Kim SJ. Transforming growth factor-beta: biology and clinical relevance. J Biochem Mol Biol 2005 ; 38 : 1-8.
69. Lahn M, Kloeker S, Berry BS. TGF-beta inhibitors for the treatment of cancer. Expert Opin Investig Drugs 2005 ; 14 : 629-43.
70. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 1998 ; 394 : 287-91.
71. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res 2002 ; 157 : 45-51.
72. Schueneman AJ, Himmelfarb E, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003 ; 63 : 4009-16.
73. Hoang T, Huang S, Armstrong E, Eickhoff JC, Harari PM. Augmentation of radiation response with the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2006 ; 64 : 1458-65.
74. Amano M, Suzuki M, Andoh S, et al. Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. Int J Clin Oncol 2007 ; 12 : 42-7.
75. Verhoeff JJ, Stalpers LJ, Van Noorden CJ, et al. Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Cancer Lett 2009 ; 285 : 39-45.
76. Classen J, Budach W. Antiangiogenesis and radiotherapy: what is the role of combined modality treatment? Curr Med Chem Anticancer Agents 2003 ; 3 : 375-82.
77. Gutin PH, Iwamoto FM, Beal K, et al. Safety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 2009 ; 75 : 156-63.
78. Gasparini G, Longo R, Toi M, Ferrara N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat Clin Pract Oncol 2005 ; 2 : 562-77.
79. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005 ; 8 : 299-309.
80. Stupp R, Ruegg C. Integrin inhibitors reaching the clinic. J Clin Oncol 2007 ; 25 : 1637-8.
81. Stupp R, Hegi ME, Neyns B, et al. Phase I/IIa Study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol 2010 ; 28 : 2712-8.
82. Steeg PS. Angiogenesis inhibitors: motivators of metastasis? Nat Med 2003 ; 9 : 822-3.
83. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature 2003 ; 423 : 593-5.
84. Blagosklonny MV. Antiangiogenic therapy tumor progression. Cancer Cell 2004 ; 5 : 13-7.
85. Anderson AR, Weaver AM, Cummings PT, Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006 ; 127 : 905-15.
86. Mazzone M, Comoglio PM. The Met pathway: master switch and drug target in cancer progression. FASEB J 2006 ; 20 : 1611-21.